We have just released a new preprint on medRxiv, led by Dr Rosie Maher, and in collaboration with colleagues at Manchester and Alder Hey Childrens Hospital on changes to the sputum proteome following patient treatment with new triple-modulator therapy for CF. Sputum proteomics can provide insights into CF lung disease mechanisms and how they are modified by therapeutic intervention, in this case ETI. This study identifies imbalances in pro- and anti- inflammatory proteins in sputum that partially resolve with ETI even in those achieving normal spirometry values. This post-ETI intermediate state could contribute to ongoing airway damage and therefore its relevance to clinical outcomes needs to be established.

The paper, titled ‘The influence of highly effective modulator therapies on the sputum proteome in cystic fibrosis’, is available here.

Comments are closed, but trackbacks and pingbacks are open.